Loss of 10q26.1-q26.3 in association with 7q34-q36.3 gain or 17q24.3-q25.3 gain predict poor outcome in pediatric medulloblastoma

Cancer Lett. 2011 Sep 28;308(2):215-24. doi: 10.1016/j.canlet.2011.05.006. Epub 2011 Jun 8.

Abstract

Medulloblastoma (MB) is the most common malignant brain tumor of childhood. We have investigated for novel chromosomal imbalances and prognostic markers of pediatric MB. Forty MBs out of 64, were analyzed using high resolution prometaphase comparative genomic hybridization. Chromosome 10q26.1-q26.3 loss combined with 17q24.3-q25.3 gain and/or 7q34-q36.3 gain in tumors predicted poor patient's survival. A minimal deleted region of 14.12cM at 10q26.1-q26.3 was refined by LOH analysis. We propose a new prognostic marker for pediatric MB patient risk stratification based on the presence of 10q26.1-q26.3 loss plus 17q24.3-q25.3 gain and/or 7q34-q36.3 gain associations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Biomarkers, Tumor* / genetics
  • Child
  • Child, Preschool
  • Chromosomes, Human, Pair 10* / genetics
  • Chromosomes, Human, Pair 17* / genetics
  • Chromosomes, Human, Pair 7* / genetics
  • Comparative Genomic Hybridization
  • Humans
  • Infant
  • Loss of Heterozygosity
  • Medulloblastoma / genetics*
  • Medulloblastoma / physiopathology
  • Multivariate Analysis
  • Prognosis
  • Treatment Outcome

Substances

  • Biomarkers, Tumor